CHMP posiive for Calquence to treat mantle cell lymphoma – AstraZeneca

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Calquence. The marketing authorisation holder for this medicinal product is AstraZeneca AB.

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending Calquence (acalabrutinib) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL), meaning it is now considered a potential treatment option for this type of cancer based on the CHMP evaluation; this includes the possibility of using Calquence as a monotherapy for patients who haven’t previously received a BTK inhibitor.